Bob Jahr serves as the Chief Executive Officer of Outlook Therapeutics, guiding the biopharmaceutical enterprise through its strategic commercialization phase. Under his executive leadership, the company focuses on the development and market introduction of LYTENAVA, an ophthalmic formulation of bevacizumab designed for the treatment of wet age-related macular degeneration and other retinal diseases. He oversees operational shifts from clinical-stage research toward regulatory execution and commercial launch preparations across domestic and international healthcare markets.